Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

Chad Fugere - VP, IR
Ian Mortimer - President & CEO
Chris Kenney - CMO
Sherry Aulin - CFO
Chris Von Seggern - CCO

Conference Call Participants

Paul Matteis - Stifel
Leo Leung - RBC Capital Markets
Tessa Romero - J.P. Morgan
Dina Ramadane - Bank of America
Luke Herrmann - Baird
Andrew Tsai - Jefferies
Paul Choi - Goldman Sachs
Peyton Bohnsack - TD Cowen
Dylan Shindler - Wedbush Securities
Basma Radwan - Leerink Partners

Operator

Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Xenon Pharmaceuticals, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].

Thank you. I would now like to turn the conference over to Mr. Chad Fugere, VP, IR for Xenon. Please go ahead.

Chad Fugere

Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's second quarter 2024 financial and operating results. Joining me today are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Sherry Aulin, Xenon's Chief Financial Officer; along with Dr. Chris Von Seggern, Xenon's Chief Commercial Officer, who will be available during the Q&A period.

Ian will begin with a summary of our recent progress across our business, including a summary of our expanding preclinical pipeline programs. Chris Kenney will provide an overview of our ongoing clinical stage programs, including our plans in major depressive disorder, or MDD. And Sherry will close with a summary of our financial results and anticipated milestones. We will then open the call up for your questions.

Please be advised that during this call, we may make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trial, the potential efficacy, safety profile, future development plans and current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners' product candidates; the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our clinical development programs, the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approvals, anticipated timing of the top-line data readout for our clinical trials of azetukalner and our expectation that we will have sufficient cash to fund operations into 2027.